Kingsview Wealth Management LLC lifted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 410.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,359 shares of the conglomerate's stock after purchasing an additional 167,564 shares during the period. Danaher accounts for approximately 0.8% of Kingsview Wealth Management LLC's holdings, making the stock its 27th largest position. Kingsview Wealth Management LLC's holdings in Danaher were worth $42,714,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. FAS Wealth Partners Inc. increased its stake in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after buying an additional 1,639 shares in the last quarter. Horizon Financial Services LLC increased its stake in Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after buying an additional 8,160 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in Danaher in the 1st quarter worth $539,000. Vision Capital Management Inc. purchased a new stake in Danaher in the 1st quarter worth $461,000. Finally, Compass Wealth Management LLC increased its stake in Danaher by 17.4% in the 1st quarter. Compass Wealth Management LLC now owns 39,764 shares of the conglomerate's stock worth $8,152,000 after buying an additional 5,891 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
DHR has been the subject of several research reports. Royal Bank Of Canada reissued an "outperform" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. Jefferies Financial Group dropped their price objective on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. HSBC dropped their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.48.
Check Out Our Latest Stock Report on Danaher
Danaher Stock Down 2.5%
DHR stock traded down $4.81 during trading on Friday, hitting $189.98. 4,239,169 shares of the company's stock traded hands, compared to its average volume of 3,524,293. The firm has a market capitalization of $135.96 billion, a P/E ratio of 36.89, a PEG ratio of 2.71 and a beta of 0.77. The business has a fifty day simple moving average of $196.12 and a two-hundred day simple moving average of $205.48. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.
Danaher Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher's dividend payout ratio (DPR) is 24.85%.
Insider Activity at Danaher
In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
